Guanine Inc logo
Clinicians reviewing rapid sepsis diagnostics
⭐ Rapid Sepsis Clarity

A Unified Diagnostic Approach to Medicine's Most Time-Critical Condition

A mobile platform delivering inflammation, infection,
and treatment read-outs in the first critical hours of sepsis.

Sepsis is one of the costliest and deadliest emergencies worldwide, yet clinicians are forced to treat it with incomplete data. While life-saving decisions must be made within the first 1–2 hours, today’s tools return results in 24–72 hours, leaving hospitals to rely on broad-spectrum antibiotics, delayed escalation, and trial-and-error management.

The core bottleneck is phenotyping—determining which antibiotics will actually work. Meanwhile, sepsis is not a single problem but a dynamic interplay between host inflammation, pathogens, and drug response. No existing platform measures all three domains together, leaving clinicians without real-time clarity on infection trajectory.

Guanine closes this gap with an integrated sepsis platform built for rapid, actionable clarity. It unifies host-response profiling, culture-free pathogen ID, and true antimicrobial phenotyping—directly from whole blood, without waiting for culture. Together, these capabilities allow ED teams to treat earlier, ICU teams to escalate with precision, and stewardship teams to finally act on comprehensive real-time data.

⭐ Integrated Sepsis Diagnostic Timeline

Sequential Generation of Clinically Actionable Information Within 120 Minutes

Guanine provides a structured, time-aligned diagnostic workflow that delivers host-response assessment, pathogen and resistance detection, and antimicrobial phenotyping within the early clinical decision window for suspected sepsis.

Guanine rapid sepsis diagnostic timeline (0–120 minutes)

Initial host-response markers are quantified at approximately 20 minutes to support early risk stratification, followed by culture-free identification of pathogens and resistance targets at approximately 60 minutes. Real-time antimicrobial phenotyping is completed within 90–120 minutes, enabling earlier evidence-based optimization of antimicrobial therapy compared with conventional culture-dependent workflows.

⭐ Responding to the ED’s Most Urgent Needs

Guanine’s Sepsis Solution (Upcoming)

Sepsis inflammation assessment icon

20-Minute Sepsis Inflammation Assessment

A rapid, quantitative host-response profile (IL-6, IL-10, CRP, PCT, TNF-α, lactate) that supports earlier recognition, risk stratification, and rule-in/rule-out decisions—before organ dysfunction begins.

Pathogen identification and AMR icon

60-Minute Broad Pathogen & Resistance Coverage

Culture-free detection of up to 64 bloodborne pathogens, including:

  • Gram-negative and Gram-positive bacteria
  • Slow-growing organisms (e.g., Mycobacteria)
  • Fungi, viruses, and protozoa

Plus an expanded panel of resistance genes, all from the same sample.

Antimicrobial phenotyping icon

~90-Minute Culture-Free Drug Susceptibility

Electrochemical phenotyping that captures real-time drug-response kinetics across 11 priority antibiotics—providing actionable susceptibility data in under two hours instead of days.

⭐ Direct Impact on Hospital Metrics

A new standard for patient safety and cost containment

Diagnostic Impact

  • One platform for all sepsis diagnostics
  • No optics. No pumps. No thermal cycling.
  • Just fast, reliable, low-cost answers at the bedside.

Hospital Impact

  • Faster time to correct therapy
  • Reduced ICU admissions and length of stay
  • Lower mortality
  • Fewer broad-spectrum antibiotic days
  • Stronger stewardship and reduced resistance pressure
  • Lower cost per patient and improved ED throughput
Explore Guanine's technology View OEM platforms